The U.K.'s drug pricing watchdog agency has deemed Amgen and Novartis' migraine treatment Aimovig too pricey for national coverage in a draft decision published Thursday.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,